Since CCL2 is implicated in the pathogenesis of diseases characterized by infiltrates containing macrophages like psoriasis, rheumatoid arthritis, multiple sclerosis, and atherosclerosis (Deshmane et al., 2009; Xia and Sui, 2009; Daly and Rollins, 2003), we postulate that TRPML2 may be an attractive novel target for the treatment of such innate immunity-related inflammatory diseases. Here, CCL2 is linked to atherosclerosis.